Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMX 001

Next Previous
Drug Profile

BMX 001

Alternative Names: BMX-001; BMX-001 free base; Manganese butoxyethyl pyridyl porphyrin - BioMimetix; MnTnBuOE-2-PyP5+

Latest Information Update: 17 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University
  • Developer BioMimetix; Duke University; University of Colorado at Denver; University of Nebraska Medical Center
  • Class Antineoplastics; Metalloporphyrins; Pyridines; Radioprotectives; Skin disorder therapies; Small molecules
  • Mechanism of Action NF-E2-related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioma
  • Phase II Rectal cancer
  • Phase I/II Anal cancer; Brain metastases; Head and neck cancer
  • Preclinical Ovarian cancer
  • No development reported Atopic dermatitis

Most Recent Events

  • 31 Dec 2024 BioMimetix completes the phase I/II BMX-HGG trial in Glioma (First line therapy, Adjunctive treatment) in USA (SC) (NCT02655601)
  • 08 Oct 2024 BioMimetix plans a phase I/II trial for Ovarian cancer and Endometrial cancer (Late-stage disease, Recurrent, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (SC), in April 2025 (NCT06620029)
  • 18 Apr 2024 BioMimetix terminates a phase I/II trial for Brain metastases in USA (SC) due to cessation of grant funding (NCT03608020)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top